- TrueVision Systems has entered a partnership agreement with Alcon for their “heads-up” 3D Digital Microscope Platform, a real-time vision system that allows surgeons (and the surgical team) to view the ophthalmic surgical field on a monitor or projector screen.
- Allergan has entered into an agreement to acquire ForSight Vision5. The deal includes an upfront payment of $95 million and a launch milestone payment for ForSight Vision5’s lead development program - a bimatoprost-eluting periocular ring for extended drug delivery in patients with glaucoma.
- Pfizer has returned its rights to PFEnex’s ranibizumab biosimilar candidate, PF582, despite Phase I/II results showing the candidate exhibits comparable safety and tolerability to ranibizumab in patients with neovascular AMD who were naïve to anti-VEGF therapy.
- Presbia Ireland (a wholly owned subsidiary of Presbia PLC) have purchased the assets of Neoptics AG, including the Swiss-based company’s comprehensive patent portfolio containing intellectual property for Microlens technology.
- In a letter to the US Department of Justice, health insurer Aetna have threatened to cut their participation in Affordable Care Act (ACA) public exchanges if they are blocked from acquiring Kentucky-based health insurer Humana.
- Several companies have released their financial figures for the second quarter of 2016: compared with the same quarter in 2015, Alimera Sciences and STAAR Surgical reported increases in revenue (66 and 12 percent, respectively); Second Sight’s revenue was $1 million, down from last year’s $2.7 million; and Ocular Therapeutix reported another net loss of $11.4 million ($1.4 million more than the same quarter in 2015).
- We interviewed James V. Mazzo about his new role at CZM and his ongoing role as Executive Chairman at Neurotech Pharmaceuticals. To find out what he had to say, click here.
This Month in Business
TrueVision and Alcon team-up on “heads-up” technology, Pfizer returns rights to ranibizumab biosimilar, and more...
9/5/2016
1 min read
